Biologics in India: bridging the gap

Section 10(4)(ii)(D) of India’s Patents Act, 1970 mandates the disclosure of the source and geographical origin of biological material whenever it’s mentioned in a patent specification but not sufficiently described in it or made available to the public.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Mylan throws down new gauntlet in Novo Wegovy patent fight

25 September 2026 Another Wegovy patent has been drawn into the long-running dispute between Mylan and Novo Nordisk over proposed generic versions of the weight-loss drug.

Pharma

Novartis defeats Orange Book challenge but suffers EU setback

24 September 2026 An Entresto Orange Book listing has survived a challenge in the US, while two trademark disputes handed Novartis contrasting fortunes at a European court.

Careers

New UK High Court judge named as replacement for Justice Meade

23 September 2026 Following the prominent patent judge’s promotion to the Court of Appeal, the judiciary has appointed a King’s Counsel with 35 years’ experience as a barrister.

More features

Beyond the primary patent: How pharma can build competitive barriers

The ‘Triple Point’ professional: Why patent success requires science, law, and technology

The UPC plugs another gap in its procedural rulebook

Trump slaps 100% tariff on generic drugs in US manufacturing push

Pharmascience v Janssen: Canada court updates methods of medical treatment protection

‘Blatant imitation’: Indian court blocks copycat pharma branding

US life sciences damages averaged $33.5m between 2019-2025

Chadha & Chadha hires former Remfry & Sagar patent partner

Biologics in India: bridging the gap

More on this story

Editor's picks

Editor's picks

More features